BlackRock Group’s Vanda Pharmaceuticals VNDA Stock Holding History

BlackRock Group’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$474K	Buy	29,709 +1,523	+5%	+$24.5K	﹤0.01%	2377
2016 Q3	$470K	Buy	28,186 +4,649	+20%	+$62.6K	﹤0.01%	2332
2016 Q2	$262K	Buy	23,537 +8,938	+61%	+$86.6K	﹤0.01%	2479
2016 Q1	$123K	Buy	14,599 +5,625	+63%	+$46.2K	﹤0.01%	2697
2015 Q4	$84K	Sell	8,974 -292	-3%	-$2.91K	﹤0.01%	2735
2015 Q3	$105K	Buy	9,266 +2,536	+38%	+$31K	﹤0.01%	2697
2015 Q2	$85K	Buy	+6,730	New	+$72.6K	﹤0.01%	2794
2014 Q3	–	Sell	-1,905	Closed	-$31K	–	2881
2014 Q2	$31K	Buy	+1,905	New	+$25.4K	﹤0.01%	2744

Other funds holding VNDA

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Group's VNDA Position: Q4 2016 in Review

BlackRock Group increased its Vanda Pharmaceuticals (VNDA) stake by 5.4% in Q4 2016, buying an estimated $24.5K and bringing the position to 29,709 shares worth $474K. The position accounts for ﹤0.01% of the portfolio, ranked #2377.

BlackRock Group first reported a position in VNDA in Q2 2014 and has held it in 8 quarters since. 141 funds tracked by Wall St. Rank hold VNDA as of Q4 2016.

BlackRock Group held 29,709 shares of Vanda Pharmaceuticals worth $474K as of Q4 2016.
BlackRock Group bought 1,523 Vanda Pharmaceuticals shares in Q4 2016, an estimated $24.5K.
Vanda Pharmaceuticals made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2377 holding.
BlackRock Group first reported a position in Vanda Pharmaceuticals in Q2 2014 and has held it in 8 quarters since.
141 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.